PTCT Q4 2019 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$5B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$96M+11.7% YoY

Gross Profit

$93M96.3% margin

Operating Income

-$73M-75.5% margin

Net Income

-$78M-80.5% margin

EPS (Diluted)

$-1.37

QoQ Revenue Growth

+35.1%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$26M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$1.0B

Stockholders' Equity

$594M

Cash & Equivalents

$288M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$96M	$86M	+11.7%
Gross Profit	$93M	$83M	+12.5%
Operating Income	-$73M	-$45M	-61.2%
Net Income	-$78M	-$48M	-60.7%

Revenue Segments

Product

$81M84%

Grant And Collaboration

$15M16%